Altis Labs was recently featured in STAT for its collaboration with AstraZeneca, where retrospective trial data was reanalysed using Altis’ AI—showing it outperformed the conventional method for predicting overall survival in lung cancer patients
As a strategic investor, we’re proud to support this Canadian company, which has developed IPRO (Imaging-Based Prognostication), an AI model that analyses imaging data early in the clinical study to predict survival outcomes more accurately. Unlike RECIST—the current standard based on simple tumour measurements—IPRO delivers a more refined, reproducible view of patient response. It can differentiate between patients who are truly responding to treatment and those with stable but less favourable prognoses and even stratify stable patients by risk level.
This deeper understanding of patient risk profiles not only enables better randomization in trial populations but also supports adaptive trial designs—where treatment regimens can be adjusted mid-trial based on evolving patient data.
Furthermore, Altis’ tool has shown promising results when applied to breast and colorectal cancer scans as well, indicating its wide-ranging applicability across different types of tumours. In addition to AstraZeneca, Altis Labs has a partnership with pharmaceutical giant Bayer; an endorsement that further strengthens its position in the industry
Read the STAT piece and learn more here.